Document is current
Any future updates will be listed below
-
Authors
Sangaletti, Sabina
Ferrara, Roberto
Tripodo, Claudio
Garassino, Marina Chiara
Colombo, Mario Paolo https://orcid.org/0000-0003-0042-7955
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG no. 22204)
Associazione Italiana per la Ricerca sul Cancro (IG no. 18425)
Ministero della Salute (Young Research Grant no. GR-2013-02355637)
- License Information
-
More Information
Article History
Received: 9 November 2020
Accepted: 13 March 2021
First Online: 2 April 2021
Compliance with ethical standards
:
: SS, CT and MPC have no conflict of Interest to declare. Dr. Roberto Ferrara reports personal fees from MSD (advisory board). Dr. Marina Chiara Garassino reports grants and personal fees from Eli Lilly, Otsuka Pharma, Astra Zeneca, Novartis, BMS, Roche, from Pfizer, Celgene, Incyte, Inivata, Bayer, MSD, GlaxoSmithKline S.p.A, Sanofi-Aventis, Spectrum Pharmaceutcials, Blueprint Medicine; personal fees from Seattle Genetics, Daiichi Sankyo, Boehringer Ingelheim, Takeda, Janssen, Mirati Therapeutics; grants from United Therapeutics Corporation, Turning Point, Merck Serono, Tiziana Sciences, Ipsen, MedImmune, Exelisis, Array (Pfizer), Clovis; non-financial support from MSD, EliLilly.
: Tumor specimens were collected from patients with NSCLC treated with ICI at the Thoracic Unit of the Istituto Nazionale dei Tumori, Milan.The study complied with the Declaration of Helsinki and was done in accordance with good clinical practice guidelines. All samples were obtained according to the Internal Review and the Ethics Boards of the Istituto Nazionale Tumori of Milan and all patients provided informed consent. All experimental protocols were approved by the ethics boards of the Istituto Nazionale Tumori of Milan (Int 22/15). Author Contribution SS, RF &MPC wrote the review, CT selected images and assembled the Figure, MG reviewed the manuscript.
